Biotechnology

First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis

YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd.  ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept h...

2024-08-06 17:00 3085

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO ® in other ASEAN markets including Thailand and Indonesia with app...

2024-08-06 08:00 2841

Everest Medicines to Announce 2024 Interim Results on August 28, 2024

SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...

2024-08-06 07:30 3961

Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001

SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced f...

2024-08-05 21:00 2385

PENTAX Medical Receives FDA Clearance for Duodenoscope with New Sterilization Technology in Collaboration with Advanced Sterilization Products.

TOKYO, Aug. 5, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA group, proudly announces FDA clearance of the DEC™ Duodenoscope (ED34-i10T2s) compatibility with the STERRAD™ 100NX Sterilizer, the flagship product from Advanced Sterilization Products (ASP), a division of Fortive. The colla...

2024-08-05 20:00 2887

DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific

DKSH has signed a strategic business partnership with Kyowa Kirin, a Japan -based global specialty pharmaceutical company, to provide comprehensive services for their specialty drugs in South Korea, Taiwan region, Singapore, Thailand, Malaysia and Hong Kong & Macau SAR. With DKSH's expertise, dis...

2024-08-05 10:34 17863

Angel Yeast Brings Together Innovative Consortium to Build Industrial Park for Synthetic Biology Development

SHANGHAI, Aug. 1, 2024 /PRNewswire/ -- Angel Yeast (SH600298), a global leader in yeast manufacturing, is spearheading an initiative that unites universities and enterprises to form an innovative consortium dedicated to advancing synthetic biology technology. This init...

2024-08-01 20:00 14115

The Director General of Pharmaceuticals and Medical Devices Visits Fapon in Indonesia

JAKARTA, Indonesia, Aug. 1, 2024 /PRNewswire/ -- The Ministry of Health of the Republic ofIndonesia, represented by the Director General of Pharmaceuticals and Medical Devices (Dirjen Falmakes), Dr. Dra. Lucia Rizka Andalucia, along with the Director of Medical Device Production and Distribution ...

2024-08-01 16:52 3277

Innovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of China

SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and meta...

2024-08-01 16:40 3369

Biosyngen Partners with Singapore's Agency for Science, Technology and Research (A*STAR) to Advance Autoimmune Therapy

GUANGZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Biosyngen has announced a strategic collaboration withSingapore's Agency for Science, Technology and Research (A*STAR) to enhance autoimmune therapy. The partnership was signed during the 14th Meeting of the Singapore-Guangdong Collaboration Council,...

2024-08-01 16:01 3564

Sirnaomics Announces a Partnership with Gore Range Capital for Establishment of a JV, Sagesse Bio, to Advance Its RNAi Therapeutics into Aesthetic Medicine

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today ...

2024-08-01 11:26 3317

Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion from the EMA

* Following approval by the European Commission, Prestige Biopharma's Herceptin biosimilar Tuznue® would become the first biosimilar from a Singaporean company to be authorized in the European Union. SINGAPORE, Aug. 1, 2024 /PRNewswire/ -- Prestige Biopharma, a pioneer in biopharmaceuticals, a...

2024-08-01 08:00 14422

Angel Yeast Driving Green Transformation Though Technological Innovation

SHANGHAI, July 31, 2024 /PRNewswire/ -- Angel Yeast (en.angelyeast.com ) (SH600298), a global leader in yeast manufacturing, is accelerating green transformation in its factory workshops by implementing a series of intelligent, automated, and sustainable technologies t...

2024-07-31 20:00 17124

Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval

SHENZHEN, China, July 31, 2024 /PRNewswire/ -- On July 28 2024, Kexing Biopharm announced European Commission approval of Apexelsin®, the generic drug to Bristol Myers Squibb's and Celgene's Abraxane®(Nab-paclitaxel). Apexelsin® is developed by WhiteOak Pharmaceutical B.V. and Kexing Biopharm is ...

2024-07-31 18:33 3485

Australian tech leading new digital biosecurity infrastructure

SYDNEY, July 31, 2024 /PRNewswire/ -- With highly pathogenic avian influenza expected to hit our shores in as little as six weeks, a real time biosecurity threat management system will be critical to response and recovery, according to Adrian Turner, co-founder of Australian tech startup ExoFlare....

2024-07-31 11:32 2859

Connext Successfully Administers First Dose of CNT201 for Dupuytren's Contracture

World's First Genetically Recombinant Collagenase Therapeutics (CNT201) Begins Clinical Trials inAustralia SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- Connext has announced the successful first administration of CNT201, its therapeutic treatment for Dupuytren's contracture, in patients. D...

2024-07-30 21:00 2888

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52,...

2024-07-29 23:18 3270

SOPHiA GENETICS Announces L'hôpital Universitaire Avicenne is Live on SOPHiA DDM™

The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that...

2024-07-29 22:30 2492

MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports

PARIS, July 26, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today announced its collaboration with renowned geneticist, Professor Yannis Pitsiladis from Hong Kong Baptist University, on sports a...

2024-07-26 19:35 4284

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2024-07-26 09:33 4179
1 ... 47484950515253 ... 186

Week's Top Stories